Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Onureg Maintenance in Japanese AML Patients
NCT05197426Phase 2Active, not recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Jan 2022
- Primary completion
- Jan 2025
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial in acute myeloid leukemia (AML) comparing Oral Azacitidine with Placebo (2 arms). Primary endpoint: Recurrence Free Survival at 17.7 months. Started Jan 2022; status: active, not recruiting.
02
Drugs
CC-486
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT05197426.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05197426.